Aktis Q2 net loss widens to $24.1 million; cash rises to $517.3 million
Aktis Oncology reported second-quarter 2026 results for the period ended June 30, 2026. Collaboration revenue rose to $3.4 million from $1.6 million, but higher research and development and general and administrative spending widened the net loss to $24.1 million from $18.1 million, and the company's cash position rose to $517.3 million after its January 2026 initial public offering.
Key points
- Net loss was $24.1 million for the quarter, compared with $18.1 million a year earlier.
- Collaboration revenue was $3.4 million, compared with $1.6 million a year earlier, tied to the Eli Lilly and Company research collaboration.
- Research and development expenses rose to $25.3 million from $18.6 million, and general and administrative expenses rose to $7.0 million from $3.9 million.
- Cash, cash equivalents, and marketable securities were $517.3 million at June 30, 2026, which the company says will fund its operating plan into 2029.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.